Karuna Therapeutics - Follow-up on Trial Evaluating KarXT in Schizophrenia

Returning guest, Dr. Andrew Miller, Founder and Chief Operating Officer of Karuna Therapeutics and lead inventor of the company's lead investigational therapy, KarXT (xanomeline-trospium), discusses positive topline results from its Phase 3 EMERGENT-2 trial evaluating KarXT in adults with schizophrenia. He talks about what these data may mean for those living with or treating schizophrenia, the potential for KarXT to change how we approach the treatment of serious mental illnesses, and the potential for progress with greater education and understanding of mental disorders.

#KarunaTherapeutics

Dr. Andrew Miller is a Founder and the Chief Operating Officer of Karuna Therapeutics. Dr. Miller is the lead inventor of Karuna’s KarXT platform and served as CEO of Karuna from 2016-2018. He served as a member of Karuna’s board of directors from April 2012 to March 2019. From August 2008 to July 2016, Dr. Miller held several positions at PureTech Health plc, last serving as a Vice President, Venture Partner, and served as Chief Operating Officer of Tal Medical, and the acting Chief Operating Officer of Entrega, Inc. He is currently a member of the board of directors of Entrega, Inc.

Dr. Miller received his bachelor’s degree in Chemical Engineering from the University of Illinois with highest honors, and his Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology, and received the MIT Presidential fellow and National Defense Science and Engineering Graduate fellowship awards. In 2016, Dr. Miller was named one of the top 40 innovators under 40 by MedTech Boston.